Subcutaneous rituximab: a practical approach?
Mené sur 127 patients atteints d'un lymphome folliculaire, cet essai multicentrique international de phase III évalue les caractéristiques pharmacocinétiques et la toxicité du rituximab par voie sous-cutanée
Rituximab, a chimeric anti-CD20 monoclonal antibody, has improved the therapeutic outcomes of patients with B-cell non-Hodgkin lymphoma of various histopathological subtypes and B-cell chronic lymphocytic leukaemia; however, its conventional administration method of intravenous infusion for up to 6 h is inconvenient and burdensome on health-care resources. An alternative strategy would be rapid rituximab infusion for 60 min or 90 min. Subcutaneous administration could be another solution, if fea ...
The Lancet Oncology , commentaire, 2013